GPC-3298306 |
GPC-3298306 |
Phase 2 Clinical |
National Cancer Center Of Japan |
Ovarian Neoplasms; Carcinoma, Hepatocellular |
Details
|
BOS-342 |
PRS-342; BOS-342; PRS-342/BOS-342 |
Phase 2 Clinical |
Pieris Pharmaceuticals |
Solid tumours; Carcinoma, Hepatocellular |
Details
|
BOXR-1030 |
BOXR-1030 |
Phase 2 Clinical |
Unum Therapeutics Inc |
Liver Neoplasms; Carcinoma, Merkel Cell; Carcinoma, Squamous Cell; Lung Neoplasms; Liposarcoma, Myxoid; Carcinoma, Hepatocellular |
Details
|
AZD-5851 |
AZD-5851; AZD5851 |
Phase 2 Clinical |
Astrazeneca Plc |
Carcinoma, Hepatocellular |
Details
|
SAR-444200 |
SAR-444200 |
Phase 2 Clinical |
Sanofi |
Solid tumours; Neoplasms |
Details
|
CAR-GPC3 T-cell (Drum Tower Hospital) |
|
Phase 2 Clinical |
Nanjing Drum Tower Hospital |
Carcinoma, Hepatocellular |
Details
|
GPC3 CAR-T therapy (Hrain Biotechnology) |
|
Phase 2 Clinical |
Hrain Biotechnology Co Ltd |
Carcinoma, Hepatocellular |
Details
|
CM-350 |
CM-350 |
Phase 2 Clinical |
Keymed Biosciences Co Ltd |
Solid tumours |
Details
|
GPC3-CAR-T cell therapy(Origincell Medical Technology) |
Ori-CAR-001; Ori-C101(OriCell) |
Phase 2 Clinical |
OriCell Therapeutics Co Ltd |
Carcinoma, Hepatocellular |
Details
|
ECT-204 |
JWATM-204; ECT-204 |
Phase 2 Clinical |
Eureka Therapeutics Inc, Jw Therapeutics (Shanghai) Co Ltd |
Liver Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung |
Details
|
Codrituzumab |
GC-33; RG-7686; RO-5137382 |
Phase 1 Clinical |
Chugai Pharmaceutical Co Ltd, F. Hoffmann-La Roche Ltd |
Solid tumours; Carcinoma, Hepatocellular |
Details
|
GPC3-T2 CAR-T cell therapy (The Second Affiliated Hospital of Guangzhou Medical University) |
|
Phase 1 Clinical |
Second Affiliated Hospital Of Guangzhou Medical University |
Carcinoma, Squamous Cell; Carcinoma, Hepatocellular |
Details
|
GLYCAR T cell therapy (Baylor College of Medicine) |
GLYCAR |
Phase 1 Clinical |
Baylor College Of Medicine |
Rhabdomyosarcoma; Liver Neoplasms; Rhabdoid Tumor; Hepatoblastoma; Wilms Tumor; Liposarcoma; Carcinoma, Hepatocellular; Endodermal Sinus Tumor |
Details
|
Anti-GPC3 CAR T-cell therapy (Nanjing University) |
|
Phase 1 Clinical |
Nanjing University |
Carcinoma, Hepatocellular |
Details
|
GPC3-CAR-T cell therapy |
CSG-GPC-3; CAR-GPC3 T-cell; GPC3-CAR/CSG-GPC3; anti-GPC-3 CAR T; KJgpc3-001; CT-011 |
Phase 1 Clinical |
Carsgen Biomedicine (Shanghai) Co Ltd |
Solid tumours; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular |
Details
|
Anti-GPC3 chimeric antigen receptor T cell therapy (Hunan Zhaotai Yongren Biotech/Guangdong Zhaotai Invivo Biomedicine) |
|
Phase 1 Clinical |
Hunan Zhaotai Yongren Biotech Co Ltd, Guangdong Zhaotai Invivo Biomedicine Co Ltd |
Carcinoma, Squamous Cell; Carcinoma, Hepatocellular |
Details
|
EU-307 |
EU307 |
Phase 1 Clinical |
Eutilex |
Liver Neoplasms; Carcinoma, Hepatocellular |
Details
|
BC-2027 |
BC2027; BC-2027 |
Phase 1 Clinical |
Biocity Biopharmaceutics Co Ltd |
Liver Neoplasms; Solid tumours |
Details
|
JMT-106 |
JMT106; JMT-106 |
Phase 1 Clinical |
CSPC Pharmaceutical Group Ltd |
Solid tumours |
Details
|
GPC3/Mesothelin-CAR-γδT Cells therapy(Second Affiliated Hospital Of Guangzhou Medical University) |
|
Phase 1 Clinical |
Second Affiliated Hospital Of Guangzhou Medical University |
Solid tumours; Liver Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Mesothelioma; Lung Neoplasms |
Details
|
NWRD-06 |
NWRD-06; NWRD06 |
Phase 1 Clinical |
Newish Technology (Beijing) Co Ltd |
Carcinoma, Hepatocellular |
Details
|
GPC3-targeted CAR-T (Peking University) |
|
Phase 1 Clinical |
Peking University |
Carcinoma, Hepatocellular |
Details
|
CAR (hYP7)-T cells (National Cancer Institute) |
|
Phase 1 Clinical |
National Cancer Institute |
Liver Neoplasms; Carcinoma, Hepatocellular |
Details
|
CT0181 |
CT-0181 |
Phase 1 Clinical |
CARsgen Therapeutics Holdings Ltd |
Carcinoma, Hepatocellular |
Details
|
TC-CAR-031 |
C-CAR-031; TC-CAR-031; TC-CAR031; C-CAR031 |
Phase 1 Clinical |
Zhejiang University, Cellular Biomedicine Group Inc |
Carcinoma, Hepatocellular |
Details
|
IM-83 CAR-T cell therapy |
IM-83; IM83 |
Phase 1 Clinical |
Beijing Immunochina Medical Science & Technology Co Ltd |
Liver Neoplasms; Neoplasms; Carcinoma, Hepatocellular |
Details
|
CT-017 |
CT-017 |
Phase 1 Clinical |
Carsgen Biomedicine (Shanghai) Co Ltd |
Carcinoma, Hepatocellular |
Details
|
JWATM-214 |
JWATM-214; JWATM214 |
Phase 1 Clinical |
Suzhou Yaomingjunuo Biotechnology Co Ltd |
Liver Neoplasms; Carcinoma, Hepatocellular |
Details
|
TH-012(Bangentai Biomedical) |
TH-012 |
Phase 1 Clinical |
Shandong Bangentai Biomedical Tech Group Co Ltd |
Stomach Neoplasms; Pancreatic Neoplasms |
Details
|
B010-A |
B010-A |
Phase 1 Clinical |
Shanghai Pharmaceuticals Holding Co Ltd |
Carcinoma, Hepatocellular |
Details
|
CT-0180 |
CT-0180 |
Phase 1 Clinical |
CARsgen Therapeutics Holdings Ltd |
Carcinoma, Hepatocellular |
Details
|
ERY-974 |
ERY-974 |
Phase 1 Clinical |
Chugai Pharmaceutical Co Ltd |
Solid tumours; Carcinoma, Hepatocellular |
Details
|
TAK-102 |
TAK-102 |
Phase 1 Clinical |
Noile-Immune Biotech Inc |
Solid tumours; Neoplasms |
Details
|
C-CAR031 CAR T-cell therapy (AbelZeta) |
C-CAR031 |
Clinical |
AbelZeta Pharma Inc |
Carcinoma, Hepatocellular |
Details
|
Anti-GPC3-IRDye800CW |
|
Clinical |
Chinese Academy Of Sciences |
|
Details
|
GPC-3298306 |
GPC-3298306 |
Phase 2 Clinical |
National Cancer Center Of Japan |
Ovarian Neoplasms; Carcinoma, Hepatocellular |
Details
|
BOS-342 |
PRS-342; BOS-342; PRS-342/BOS-342 |
Phase 2 Clinical |
Pieris Pharmaceuticals |
Solid tumours; Carcinoma, Hepatocellular |
Details
|
BOXR-1030 |
BOXR-1030 |
Phase 2 Clinical |
Unum Therapeutics Inc |
Liver Neoplasms; Carcinoma, Merkel Cell; Carcinoma, Squamous Cell; Lung Neoplasms; Liposarcoma, Myxoid; Carcinoma, Hepatocellular |
Details
|
AZD-5851 |
AZD-5851; AZD5851 |
Phase 2 Clinical |
Astrazeneca Plc |
Carcinoma, Hepatocellular |
Details
|
SAR-444200 |
SAR-444200 |
Phase 2 Clinical |
Sanofi |
Solid tumours; Neoplasms |
Details
|
CAR-GPC3 T-cell (Drum Tower Hospital) |
|
Phase 2 Clinical |
Nanjing Drum Tower Hospital |
Carcinoma, Hepatocellular |
Details
|
GPC3 CAR-T therapy (Hrain Biotechnology) |
|
Phase 2 Clinical |
Hrain Biotechnology Co Ltd |
Carcinoma, Hepatocellular |
Details
|
CM-350 |
CM-350 |
Phase 2 Clinical |
Keymed Biosciences Co Ltd |
Solid tumours |
Details
|
GPC3-CAR-T cell therapy(Origincell Medical Technology) |
Ori-CAR-001; Ori-C101(OriCell) |
Phase 2 Clinical |
OriCell Therapeutics Co Ltd |
Carcinoma, Hepatocellular |
Details
|
ECT-204 |
JWATM-204; ECT-204 |
Phase 2 Clinical |
Eureka Therapeutics Inc, Jw Therapeutics (Shanghai) Co Ltd |
Liver Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung |
Details
|
Codrituzumab |
GC-33; RG-7686; RO-5137382 |
Phase 1 Clinical |
Chugai Pharmaceutical Co Ltd, F. Hoffmann-La Roche Ltd |
Solid tumours; Carcinoma, Hepatocellular |
Details
|
GPC3-T2 CAR-T cell therapy (The Second Affiliated Hospital of Guangzhou Medical University) |
|
Phase 1 Clinical |
Second Affiliated Hospital Of Guangzhou Medical University |
Carcinoma, Squamous Cell; Carcinoma, Hepatocellular |
Details
|
GLYCAR T cell therapy (Baylor College of Medicine) |
GLYCAR |
Phase 1 Clinical |
Baylor College Of Medicine |
Rhabdomyosarcoma; Liver Neoplasms; Rhabdoid Tumor; Hepatoblastoma; Wilms Tumor; Liposarcoma; Carcinoma, Hepatocellular; Endodermal Sinus Tumor |
Details
|
Anti-GPC3 CAR T-cell therapy (Nanjing University) |
|
Phase 1 Clinical |
Nanjing University |
Carcinoma, Hepatocellular |
Details
|
GPC3-CAR-T cell therapy |
CSG-GPC-3; CAR-GPC3 T-cell; GPC3-CAR/CSG-GPC3; anti-GPC-3 CAR T; KJgpc3-001; CT-011 |
Phase 1 Clinical |
Carsgen Biomedicine (Shanghai) Co Ltd |
Solid tumours; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular |
Details
|
Anti-GPC3 chimeric antigen receptor T cell therapy (Hunan Zhaotai Yongren Biotech/Guangdong Zhaotai Invivo Biomedicine) |
|
Phase 1 Clinical |
Hunan Zhaotai Yongren Biotech Co Ltd, Guangdong Zhaotai Invivo Biomedicine Co Ltd |
Carcinoma, Squamous Cell; Carcinoma, Hepatocellular |
Details
|
EU-307 |
EU307 |
Phase 1 Clinical |
Eutilex |
Liver Neoplasms; Carcinoma, Hepatocellular |
Details
|
BC-2027 |
BC2027; BC-2027 |
Phase 1 Clinical |
Biocity Biopharmaceutics Co Ltd |
Liver Neoplasms; Solid tumours |
Details
|
JMT-106 |
JMT106; JMT-106 |
Phase 1 Clinical |
CSPC Pharmaceutical Group Ltd |
Solid tumours |
Details
|
GPC3/Mesothelin-CAR-γδT Cells therapy(Second Affiliated Hospital Of Guangzhou Medical University) |
|
Phase 1 Clinical |
Second Affiliated Hospital Of Guangzhou Medical University |
Solid tumours; Liver Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Mesothelioma; Lung Neoplasms |
Details
|
NWRD-06 |
NWRD-06; NWRD06 |
Phase 1 Clinical |
Newish Technology (Beijing) Co Ltd |
Carcinoma, Hepatocellular |
Details
|
GPC3-targeted CAR-T (Peking University) |
|
Phase 1 Clinical |
Peking University |
Carcinoma, Hepatocellular |
Details
|
CAR (hYP7)-T cells (National Cancer Institute) |
|
Phase 1 Clinical |
National Cancer Institute |
Liver Neoplasms; Carcinoma, Hepatocellular |
Details
|
CT0181 |
CT-0181 |
Phase 1 Clinical |
CARsgen Therapeutics Holdings Ltd |
Carcinoma, Hepatocellular |
Details
|
TC-CAR-031 |
C-CAR-031; TC-CAR-031; TC-CAR031; C-CAR031 |
Phase 1 Clinical |
Zhejiang University, Cellular Biomedicine Group Inc |
Carcinoma, Hepatocellular |
Details
|
IM-83 CAR-T cell therapy |
IM-83; IM83 |
Phase 1 Clinical |
Beijing Immunochina Medical Science & Technology Co Ltd |
Liver Neoplasms; Neoplasms; Carcinoma, Hepatocellular |
Details
|
CT-017 |
CT-017 |
Phase 1 Clinical |
Carsgen Biomedicine (Shanghai) Co Ltd |
Carcinoma, Hepatocellular |
Details
|
JWATM-214 |
JWATM-214; JWATM214 |
Phase 1 Clinical |
Suzhou Yaomingjunuo Biotechnology Co Ltd |
Liver Neoplasms; Carcinoma, Hepatocellular |
Details
|
TH-012(Bangentai Biomedical) |
TH-012 |
Phase 1 Clinical |
Shandong Bangentai Biomedical Tech Group Co Ltd |
Stomach Neoplasms; Pancreatic Neoplasms |
Details
|
B010-A |
B010-A |
Phase 1 Clinical |
Shanghai Pharmaceuticals Holding Co Ltd |
Carcinoma, Hepatocellular |
Details
|
CT-0180 |
CT-0180 |
Phase 1 Clinical |
CARsgen Therapeutics Holdings Ltd |
Carcinoma, Hepatocellular |
Details
|
ERY-974 |
ERY-974 |
Phase 1 Clinical |
Chugai Pharmaceutical Co Ltd |
Solid tumours; Carcinoma, Hepatocellular |
Details
|
TAK-102 |
TAK-102 |
Phase 1 Clinical |
Noile-Immune Biotech Inc |
Solid tumours; Neoplasms |
Details
|
C-CAR031 CAR T-cell therapy (AbelZeta) |
C-CAR031 |
Clinical |
AbelZeta Pharma Inc |
Carcinoma, Hepatocellular |
Details
|
Anti-GPC3-IRDye800CW |
|
Clinical |
Chinese Academy Of Sciences |
|
Details
|